Eyetech Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Eyetech Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Eyetech Pharmaceuticals: 5 sponsored US clinical trials, none currently recruiting.
Eyetech Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Retinal Vein Occlusion, with 1 trials.
Upper-quartile sponsor footprint
Eyetech Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00312351
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
NCT00134667
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
NCT00088192
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
NCT00088283
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 2 |
Therapeutic Areas
How the Eyetech Pharmaceuticals archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Retinal Vein Occlusion (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Eyetech Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Eyetech Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Eyetech Pharmaceuticals page
5 registered trials is a research-attention snapshot, not an endorsement of Eyetech Pharmaceuticals or any single study.
- None of Eyetech Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Retinal Vein Occlusion is the condition Eyetech Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Retinal Vein Occlusion trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eyetech Pharmaceuticals pipeline card: 5 registered trials from official public datasets.Report a data error.